Intellipharmaceutics International Inc. (OTCPK: IPCI.Q)
Health Care · Pharmaceuticals · CA
$—
— today · — 1Y
Intellipharmaceutics International Inc. (OTCPK: IPCI.Q) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $33.00 and employs 11 people.
trading between 0.00 and 0.00.
Tweenvest scores Intellipharmaceutics International Inc. across four factors: quality 10/100. Its strongest factor is quality.
IPCI.Q price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $33.00
- Revenue (TTM)
- $904.95K
- P/E
- —
- EPS
- -0.09
- Dividend yield
- —
- Beta (5Y)
- 1.26
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 33.09M
- Employees
- 11
- Next earnings
- —
About Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
- ISIN
- CA4581733090
- Founded
- 1998
- Listed since
- Jul 22, 1999
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,199.54 | -2.77% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.17 | -1.09% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.68 | -1.77% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.46 | -0.40% |
Figures last refreshed Aug 18, 2026.